Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent a significant advancement in cancer therapy, now serving as a first-line maintenance treatment for ovarian cancer.
• PARPi have also gained approval for treating breast, pancreatic, and prostate cancers, demonstrating broad clinical utility.

Purpose of the Study:

• To review the mechanisms of Poly(ADP-ribose) polymerase inhibitor resistance.
• To focus on resistance mechanisms identified in clinical settings.
• To highlight challenges in characterizing clinical Poly(ADP-ribose) polymerase inhibitor resistance and propose strategies for prevention and overcoming it.

Main Methods:

• Literature review of pre-clinical models and clinical studies on Poly(ADP-ribose) polymerase inhibitor resistance.
• Analysis of reported resistance mechanisms in various cancer types.
• Synthesis of current understanding and future directions in managing Poly(ADP-ribose) polymerase inhibitor resistance.

Main Results:

• Resistance to Poly(ADP-ribose) polymerase inhibitors (PARPi) is a clinically observed phenomenon, leading to an unmet medical need.
• Mechanisms of PARPi resistance have been elucidated in pre-clinical settings and increasingly identified in clinical practice.
• Characterizing the full clinical landscape of PARPi resistance presents significant challenges.

Conclusions:

• Understanding the diverse mechanisms of Poly(ADP-ribose) polymerase inhibitor resistance is crucial for effective cancer treatment.
• Addressing clinical resistance requires further research into its complexities.
• Developing strategies to prevent and overcome Poly(ADP-ribose) polymerase inhibitor resistance is essential to improve patient outcomes in ovarian, breast, pancreatic, and prostate cancers.